Skip to main content

Table 1 Model Parameters

From: Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US

Parameters Value Probability distribution
Baseline age 40
Background mortality rate [30] US life tables
Monthly chance of death from hospitalization [31] 0.0248 Beta(1.099, 43.224)
Direct cost (2013-$US) [2, 3]   
Standard therapy costs (per person week)a
 Controlled $46
 Partially controlled $47
 Uncontrolled $53
Treatment costs (per person week) [2, 3, 10, 21, 22]
 Tiotropium $13
 Omalizumab $437
Cost of exacerbations (per person week) [2, 3]
 Non-severe exacerbation $130 Gamma(100, 0.77)
 Severe exacerbation without hospitalization $594 Gamma(98.01, 0.17)
 Hospitalization $9900 Gamma(100.08, 0.01)
Indirect cost (per person week) (used only for sensitivity analysis) [1, 4, 22]
 Controlled $165
 Partially controlled $185
 Uncontrolled $312
 Exacerbation (Including not severe exacerbation, severe exacerbation and hospitalization) $856
Health state utility values [10, 21, 22]
 Controlled 0.937 Beta(982.3883, 66.0517)
 Partially controlled 0.907 Beta(378.5135, 38.8112)
 Uncontrolled 0.728 Beta(1212.6010, 453.0598)
 Non-severe exacerbation 0.649 Beta(1243.7040, 672.6349)
 Severe exacerbation without hospitalization 0.570 Beta(1175.3160, 886.6418)
 Hospitalization 0.330 Beta(613.7850, 1246.1690)
  1. All costs are adjusted to 2013 US dollars using US consumer price index [22]
  2. Gamma(x, y) distribution with shape parameter x, and rate parameter y, Beta(x, y) beta distribution with shape1 parameter x, and shape2 parameter y
  3. aDetails in the (Additional file 1: Appendix-1)